AMPH Key Statistics, Chart & Performance
The current stock price of AMPH is 25.4 USD. In the past month the price increased by 0.96%. In the past year, price decreased by -32.78%.
AMPH Latest News, Press Relases and Analysis
AMPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.56 | 988.66B | ||
| JNJ | JOHNSON & JOHNSON | 20.23 | 505.81B | ||
| MRK | MERCK & CO. INC. | 11.12 | 243.06B | ||
| PFE | PFIZER INC | 7.86 | 142.97B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.16 | 109.00B | ||
| ZTS | ZOETIS INC | 19.53 | 54.56B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.23 | 21.89B | ||
| VTRS | VIATRIS INC | 4.94 | 13.26B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.36 | 11.14B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.86 | 8.41B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.34B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.04B |
Related stock screener links
About AMPH
Company Profile
Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. The company is headquartered in Rancho Cucamonga, California and currently employs 2,028 full-time employees. The company went IPO on 2014-06-25. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The firm manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The firm manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
Company Info
AMPHASTAR PHARMACEUTICALS IN
11570 6th St
Rancho Cucamonga CALIFORNIA 91730 US
CEO: Jack Y. Zhang
Employees: 2028
Phone: 19099809484
AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ
What does AMPH do?
Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. The company is headquartered in Rancho Cucamonga, California and currently employs 2,028 full-time employees. The company went IPO on 2014-06-25. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The firm manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The firm manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
Can you provide the latest stock price for AMPHASTAR PHARMACEUTICALS IN?
The current stock price of AMPH is 25.4 USD. The price decreased by -3.46% in the last trading session.
What is the dividend status of AMPHASTAR PHARMACEUTICALS IN?
AMPH does not pay a dividend.
How is the ChartMill rating for AMPHASTAR PHARMACEUTICALS IN?
AMPH has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is AMPHASTAR PHARMACEUTICALS IN worth?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a market capitalization of 1.17B USD. This makes AMPH a Small Cap stock.
What is the next earnings date for AMPH stock?
AMPHASTAR PHARMACEUTICALS IN (AMPH) will report earnings on 2026-02-25, after the market close.
AMPH Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to AMPH. When comparing the yearly performance of all stocks, AMPH is a bad performer in the overall market: 84.31% of all stocks are doing better.
AMPH Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to AMPH. AMPH scores excellent on profitability, but there are some minor concerns on its financial health.
AMPH Financial Highlights
Over the last trailing twelve months AMPH reported a non-GAAP Earnings per Share(EPS) of 3.44. The EPS decreased by -9.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.43% | ||
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| Debt/Equity | 0.78 |
AMPH Forecast & Estimates
12 analysts have analysed AMPH and the average price target is 32.64 USD. This implies a price increase of 28.5% is expected in the next year compared to the current price of 25.4.
For the next year, analysts expect an EPS growth of -8.67% and a revenue growth -0.81% for AMPH